ES2102009T3 - Tratamiento para el asma. - Google Patents

Tratamiento para el asma.

Info

Publication number
ES2102009T3
ES2102009T3 ES93902914T ES93902914T ES2102009T3 ES 2102009 T3 ES2102009 T3 ES 2102009T3 ES 93902914 T ES93902914 T ES 93902914T ES 93902914 T ES93902914 T ES 93902914T ES 2102009 T3 ES2102009 T3 ES 2102009T3
Authority
ES
Spain
Prior art keywords
asthma
treatment
eosinophils
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902914T
Other languages
English (en)
Other versions
ES2102009T5 (es
Inventor
Roy R Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25234272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2102009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of ES2102009T3 publication Critical patent/ES2102009T3/es
Application granted granted Critical
Publication of ES2102009T5 publication Critical patent/ES2102009T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE PRESENTA UN METODO PARA EL TRATAMIENTO DEL ASMA. EL METODO COMPRENDE LA ADMINISTRACION DE UN ANTICUERPO, POLIPEPTIDO U OTRA MOLECULA QUE RECONOCE VLA-4, UNA PROTEINA EXPRESADA SOBRE LA SUPERFICIE DE CIERTOS LEUCOCITOS TALES COMO EOSINOFILOS.
ES93902914T 1992-01-13 1993-01-12 Tratamiento para el asma. Expired - Lifetime ES2102009T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82176892A 1992-01-13 1992-01-13

Publications (2)

Publication Number Publication Date
ES2102009T3 true ES2102009T3 (es) 1997-07-16
ES2102009T5 ES2102009T5 (es) 2004-12-16

Family

ID=25234272

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902914T Expired - Lifetime ES2102009T5 (es) 1992-01-13 1993-01-12 Tratamiento para el asma.

Country Status (9)

Country Link
EP (1) EP0626861B2 (es)
JP (4) JPH07506091A (es)
AT (1) ATE150319T1 (es)
CA (1) CA2127462C (es)
DE (1) DE69309044T3 (es)
DK (1) DK0626861T4 (es)
ES (1) ES2102009T5 (es)
GR (1) GR3023203T3 (es)
WO (1) WO1993013798A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
CA2153692C (en) * 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
ES2114183T5 (es) * 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100628818B1 (ko) 1998-09-14 2006-09-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 인테그린 길항제를 사용하여 다발성 골수종 및 골수종에의한 골흡수를 치료하는 방법
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PT1173201E (pt) * 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK2314315T3 (en) 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
KR20110098980A (ko) 2003-12-22 2011-09-02 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP2839843B1 (en) 2006-05-25 2018-06-20 Biogen MA Inc. VLA-1 antagonist for use in treating stroke
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
HUE050858T2 (hu) 2010-04-16 2021-01-28 Biogen Ma Inc VLA-4 ellenes antitestek
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
AU2021210669A1 (en) 2020-01-24 2022-08-18 Pfizer Inc. Anti-E-selectin antibodies, compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) † 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) † 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
GR3023203T3 (en) 1997-07-30
JP4590152B2 (ja) 2010-12-01
WO1993013798A1 (en) 1993-07-22
EP0626861B2 (en) 2004-04-28
DE69309044D1 (de) 1997-04-24
ES2102009T5 (es) 2004-12-16
CA2127462A1 (en) 1993-07-22
AU3431793A (en) 1993-08-03
JP2003176239A (ja) 2003-06-24
DK0626861T3 (da) 1997-09-22
DK0626861T4 (da) 2004-08-16
HK1007682A1 (en) 1999-04-23
DE69309044T2 (de) 1997-09-25
EP0626861B1 (en) 1997-03-19
EP0626861A1 (en) 1994-12-07
ATE150319T1 (de) 1997-04-15
DE69309044T3 (de) 2004-12-23
JP2010285444A (ja) 2010-12-24
JP2006316070A (ja) 2006-11-24
AU665232B2 (en) 1995-12-21
CA2127462C (en) 1999-03-23
JPH07506091A (ja) 1995-07-06

Similar Documents

Publication Publication Date Title
ES2102009T5 (es) Tratamiento para el asma.
ES2114183T3 (es) Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
ITTO920695A0 (it) Sistema di riconoscimento, particolarmente per il riconoscimento di persone
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
NO971875D0 (no) Cathepsin 02 protease
FI943389L (fi) Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö
IT8819077A0 (it) Processo per la preparazione di 1,2 difluoroetano e di 1,1,2trifluoroetano.
AU5421594A (en) Recombinant method and host for manufacture of xylitol
ATE64619T1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
GR3026519T3 (en) New method of treating depression
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
DK0646176T3 (da) Levering og ekspression af et hybridoverfladeprotein på overfladen af grampositive bakterier
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
DE69002881D1 (de) Peptide und deren Benutzung.
EP0235904A3 (en) Treatment of allergy with thymopentin
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
ITRM940253A0 (it) "procedimento per la produzione di policarbonato".
BR9205877A (pt) Processo e composiçao para o tratamento de infecçoes por herpes.
SE8800981D0 (sv) A recombinant fusion protein, its use and a recombinant vector
ITTO921024A1 (it) Procedimento per la fabbricazione di nastri pieghettatori e increspatori fissabili mediante contatto.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626861

Country of ref document: ES